Systemic treatments deliver their active principle into the body without specific distribution, while topical agents deliver the active principle at the site of the disease – but active concentrations are usually too low and too short to provide rapid and sustained efficacy.

This has been overcome with the development of mucoadhesive buccal tablets with sustained release properties.

The mucoadhesive dosage forms offer prolonged contact at the site of administration, low enzymatic activity, and patient’s compliance.

Vectans pharma owns a unique technology that opens the way to a new therapeutic horizon: the sustained release muco-adhesive drug delivery system, a new route of administration delivering early, high and prolonged concentrations of an active substance at the disease’s site.